2001
URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1
Brown F, Nikolic-Paterson D, Chadban S, Dowling J, Jose M, Metz C, Bucala R, Atkins R. URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1. Transplantation 2001, 71: 1777-1783. PMID: 11455258, DOI: 10.1097/00007890-200106270-00013.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorAcute rejectionMIF concentrationsRenal transplant patientsCyA toxicityTransplant patientsProspective studyRetrospective studyNormal controlsSerum macrophage migration inhibitory factorUrine macrophage migration inhibitory factorAcute renal allograft rejectionStable renal transplant patientsDay 1 posttransplantationEpisodes of biopsyLocal MIF productionRenal allograft patientsRENAL ALLOGRAFT REJECTION1Renal transplant dysfunctionSerum MIF concentrationsSerum MIF levelsTransplant patient groupsRenal allograft rejectionPro-inflammatory cytokinesNormal healthy controls
1997
Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney International 1997, 52: 1645-1650. PMID: 9407512, DOI: 10.1038/ki.1997.497.Peer-Reviewed Original ResearchMeSH KeywordsApolipoproteins BFemaleGlycation End Products, AdvancedHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRenal DialysisUremiaConceptsAdvanced glycation endoproductsLow density lipoprotein clearanceLong-term hemodialysis therapyRenal replacement treatmentEffect of hemodialysisAGE removalDiabetic ESRDSerum apoBESRD patientsRenal insufficiencyClinical outcomesLipoprotein clearancePlasma apoBHemodialysis therapyReplacement treatmentApoliprotein BPatientsGroup subjectsHemodialysis filtersReactive substancesApoBPlasma apolipoproteinsAGE clearanceBaselineClearance